| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostate | 41 | 2022 | 435 | 4.850 |
Why?
|
| Prostatic Neoplasms | 54 | 2022 | 1547 | 4.240 |
Why?
|
| Stromal Cells | 31 | 2017 | 299 | 3.450 |
Why?
|
| Transforming Growth Factor beta | 17 | 2014 | 459 | 2.100 |
Why?
|
| Receptors, Androgen | 20 | 2022 | 415 | 1.770 |
Why?
|
| Tumor Microenvironment | 12 | 2022 | 545 | 1.450 |
Why?
|
| Proteins | 11 | 2014 | 1046 | 1.180 |
Why?
|
| Prostatic Hyperplasia | 7 | 2011 | 117 | 1.030 |
Why?
|
| Fibroblasts | 9 | 2014 | 891 | 0.950 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 88 | 0.910 |
Why?
|
| Wound Healing | 5 | 2014 | 458 | 0.780 |
Why?
|
| Cell Line, Tumor | 26 | 2022 | 3338 | 0.770 |
Why?
|
| Transforming Growth Factor beta1 | 9 | 2014 | 129 | 0.760 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2021 | 16 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 59 | 0.740 |
Why?
|
| Androgens | 6 | 2022 | 275 | 0.710 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2017 | 1898 | 0.670 |
Why?
|
| Carcinoma | 4 | 2017 | 285 | 0.670 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2014 | 107 | 0.660 |
Why?
|
| Interleukin-8 | 3 | 2011 | 209 | 0.650 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2017 | 66 | 0.650 |
Why?
|
| Extracellular Matrix | 6 | 2022 | 233 | 0.640 |
Why?
|
| Mice, Nude | 14 | 2018 | 710 | 0.640 |
Why?
|
| Male | 86 | 2022 | 61283 | 0.630 |
Why?
|
| Inflammation | 4 | 2014 | 1428 | 0.560 |
Why?
|
| Myofibroblasts | 2 | 2014 | 75 | 0.540 |
Why?
|
| Animals | 68 | 2021 | 34185 | 0.540 |
Why?
|
| Neoplasm Invasiveness | 8 | 2017 | 611 | 0.520 |
Why?
|
| Mice | 42 | 2021 | 17746 | 0.520 |
Why?
|
| Tumor Cells, Cultured | 15 | 2016 | 1066 | 0.500 |
Why?
|
| Muscle, Smooth | 6 | 2004 | 137 | 0.500 |
Why?
|
| Adenocarcinoma | 6 | 2014 | 1000 | 0.480 |
Why?
|
| Protein Biosynthesis | 4 | 2004 | 665 | 0.470 |
Why?
|
| Tenascin | 4 | 2022 | 31 | 0.470 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 39 | 0.460 |
Why?
|
| Cell Line | 14 | 2020 | 2771 | 0.460 |
Why?
|
| Epithelial Cells | 8 | 2018 | 910 | 0.460 |
Why?
|
| Neoplasms | 5 | 2014 | 2788 | 0.450 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 108 | 0.440 |
Why?
|
| Epithelium | 5 | 2011 | 362 | 0.440 |
Why?
|
| Neovascularization, Pathologic | 6 | 2007 | 242 | 0.430 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 2058 | 0.420 |
Why?
|
| Chemokines | 3 | 2012 | 135 | 0.420 |
Why?
|
| Cellular Reprogramming | 1 | 2014 | 116 | 0.420 |
Why?
|
| Cell Division | 11 | 2014 | 782 | 0.410 |
Why?
|
| Urinary Bladder Neoplasms | 8 | 2019 | 557 | 0.410 |
Why?
|
| Humans | 79 | 2022 | 124790 | 0.410 |
Why?
|
| Macrophages | 3 | 2014 | 618 | 0.400 |
Why?
|
| Disease Progression | 12 | 2019 | 2052 | 0.390 |
Why?
|
| Ganglia, Spinal | 5 | 2006 | 71 | 0.380 |
Why?
|
| Growth Inhibitors | 3 | 1998 | 37 | 0.370 |
Why?
|
| Transcription Factors | 1 | 2021 | 2609 | 0.370 |
Why?
|
| Neurogenesis | 2 | 2013 | 190 | 0.360 |
Why?
|
| Ganglia | 1 | 2010 | 20 | 0.360 |
Why?
|
| Dihydrotestosterone | 10 | 2004 | 67 | 0.350 |
Why?
|
| Models, Biological | 3 | 2017 | 1461 | 0.340 |
Why?
|
| Serine Endopeptidases | 3 | 2017 | 175 | 0.340 |
Why?
|
| Thrombospondins | 1 | 2009 | 14 | 0.320 |
Why?
|
| Urogenital System | 4 | 1995 | 34 | 0.320 |
Why?
|
| Neurites | 3 | 2006 | 42 | 0.310 |
Why?
|
| Transplantation, Heterologous | 5 | 2009 | 255 | 0.300 |
Why?
|
| Aging | 3 | 2015 | 1189 | 0.300 |
Why?
|
| Pancreas | 1 | 2009 | 217 | 0.300 |
Why?
|
| Cell Proliferation | 10 | 2020 | 2304 | 0.290 |
Why?
|
| Immunohistochemistry | 9 | 2016 | 1690 | 0.290 |
Why?
|
| Zika Virus | 2 | 2020 | 142 | 0.290 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 282 | 0.280 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 670 | 0.280 |
Why?
|
| Rats | 19 | 2009 | 3689 | 0.280 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 55 | 0.280 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2008 | 43 | 0.280 |
Why?
|
| Homeostasis | 1 | 2011 | 692 | 0.280 |
Why?
|
| Coculture Techniques | 6 | 2014 | 233 | 0.280 |
Why?
|
| Cell Differentiation | 6 | 2021 | 1929 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 3 | 2009 | 687 | 0.270 |
Why?
|
| Benzamides | 2 | 2018 | 106 | 0.260 |
Why?
|
| Mice, Transgenic | 8 | 2016 | 2410 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 1135 | 0.260 |
Why?
|
| Immediate-Early Proteins | 2 | 2005 | 58 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 5 | 2022 | 257 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 10 | 2018 | 4431 | 0.250 |
Why?
|
| Tissue Array Analysis | 4 | 2019 | 137 | 0.250 |
Why?
|
| Receptors, Calcitriol | 2 | 2017 | 71 | 0.250 |
Why?
|
| Cell Communication | 3 | 2009 | 167 | 0.250 |
Why?
|
| Loss of Heterozygosity | 2 | 2008 | 125 | 0.250 |
Why?
|
| Cell Lineage | 2 | 2019 | 348 | 0.240 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 868 | 0.240 |
Why?
|
| Cell Nucleus | 5 | 2004 | 677 | 0.240 |
Why?
|
| Myoblasts | 1 | 2004 | 30 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 618 | 0.230 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 2509 | 0.220 |
Why?
|
| Receptors, Steroid | 9 | 1988 | 275 | 0.220 |
Why?
|
| Prostatectomy | 5 | 2022 | 344 | 0.210 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 501 | 0.210 |
Why?
|
| 3T3 Cells | 4 | 2018 | 129 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 1998 | 776 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 1291 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2016 | 1019 | 0.200 |
Why?
|
| Cytoplasm | 3 | 2004 | 291 | 0.190 |
Why?
|
| Glucuronosyltransferase | 1 | 2022 | 69 | 0.190 |
Why?
|
| Interleukin-1alpha | 1 | 2021 | 8 | 0.190 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 119 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 1604 | 0.190 |
Why?
|
| Collagen | 2 | 2019 | 315 | 0.190 |
Why?
|
| Protein Precursors | 2 | 2002 | 153 | 0.190 |
Why?
|
| Blotting, Western | 4 | 2014 | 1110 | 0.190 |
Why?
|
| Mesoderm | 2 | 2011 | 113 | 0.190 |
Why?
|
| Semaphorins | 2 | 2013 | 31 | 0.190 |
Why?
|
| Apoptosis | 6 | 2014 | 1791 | 0.190 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 429 | 0.190 |
Why?
|
| Zika Virus Infection | 2 | 2020 | 169 | 0.180 |
Why?
|
| Protein Isoforms | 1 | 2022 | 412 | 0.180 |
Why?
|
| Cell Movement | 5 | 2017 | 835 | 0.180 |
Why?
|
| Biomarkers, Tumor | 4 | 2022 | 1466 | 0.180 |
Why?
|
| Antibodies | 5 | 2006 | 372 | 0.180 |
Why?
|
| Receptors, CXCR3 | 1 | 2020 | 21 | 0.180 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 271 | 0.180 |
Why?
|
| Bone and Bones | 2 | 2017 | 266 | 0.180 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 53 | 0.180 |
Why?
|
| Granulocytes | 1 | 2020 | 66 | 0.180 |
Why?
|
| RNA Helicases | 1 | 2021 | 63 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 47 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2018 | 3753 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2000 | 150 | 0.170 |
Why?
|
| Nitriles | 2 | 2014 | 146 | 0.170 |
Why?
|
| Vimentin | 4 | 2009 | 66 | 0.170 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2019 | 160 | 0.170 |
Why?
|
| Uridine Diphosphate Glucose Dehydrogenase | 1 | 2019 | 5 | 0.160 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2019 | 7 | 0.160 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 35 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 51 | 0.160 |
Why?
|
| Membrane Proteins | 3 | 2013 | 1527 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 316 | 0.160 |
Why?
|
| Cell Plasticity | 1 | 2019 | 32 | 0.160 |
Why?
|
| Genetic Therapy | 5 | 2003 | 683 | 0.160 |
Why?
|
| RNA, Messenger | 5 | 2016 | 2825 | 0.160 |
Why?
|
| Peripheral Nerves | 3 | 2008 | 85 | 0.160 |
Why?
|
| Neoplasm Transplantation | 7 | 2013 | 374 | 0.160 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 95 | 0.150 |
Why?
|
| Connective Tissue | 3 | 1995 | 21 | 0.150 |
Why?
|
| Monocytes | 1 | 2020 | 354 | 0.150 |
Why?
|
| Up-Regulation | 7 | 2016 | 867 | 0.150 |
Why?
|
| Virus Replication | 2 | 2020 | 611 | 0.150 |
Why?
|
| Peptide Fragments | 2 | 2002 | 779 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 487 | 0.150 |
Why?
|
| Disulfides | 1 | 1998 | 78 | 0.150 |
Why?
|
| Denervation | 1 | 2017 | 29 | 0.140 |
Why?
|
| Viral Tropism | 1 | 2018 | 43 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2018 | 155 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2017 | 321 | 0.140 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2017 | 38 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2020 | 4542 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 1998 | 530 | 0.140 |
Why?
|
| Integrins | 1 | 2017 | 82 | 0.140 |
Why?
|
| Genetic Vectors | 6 | 2013 | 940 | 0.140 |
Why?
|
| Neoplasm Proteins | 3 | 2014 | 670 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 886 | 0.130 |
Why?
|
| Retroviridae | 1 | 2017 | 196 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 510 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2016 | 112 | 0.130 |
Why?
|
| Phenotype | 5 | 2017 | 4260 | 0.130 |
Why?
|
| Jagged-1 Protein | 1 | 2016 | 53 | 0.130 |
Why?
|
| Connective Tissue Cells | 2 | 1995 | 5 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 34 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 307 | 0.130 |
Why?
|
| Wnt Proteins | 2 | 2013 | 195 | 0.130 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2017 | 139 | 0.130 |
Why?
|
| Actins | 3 | 2009 | 342 | 0.130 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 66 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2013 | 1495 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 130 | 0.120 |
Why?
|
| Organoids | 2 | 2017 | 284 | 0.120 |
Why?
|
| Base Sequence | 3 | 2010 | 3099 | 0.120 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2014 | 168 | 0.120 |
Why?
|
| Mice, Inbred C3H | 7 | 2000 | 118 | 0.120 |
Why?
|
| Mitogens | 1 | 1995 | 31 | 0.120 |
Why?
|
| beta 2-Microglobulin | 1 | 1995 | 34 | 0.120 |
Why?
|
| Microvessels | 1 | 2015 | 55 | 0.120 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2017 | 167 | 0.120 |
Why?
|
| Pteridines | 1 | 2014 | 8 | 0.120 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 4357 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 6 | 1 | 2014 | 10 | 0.120 |
Why?
|
| Phenylthiohydantoin | 1 | 2014 | 12 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 720 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 26 | 0.120 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 667 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 551 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 211 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 260 | 0.120 |
Why?
|
| Osteopontin | 1 | 2014 | 49 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 530 | 0.110 |
Why?
|
| Fibronectins | 1 | 2014 | 104 | 0.110 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2014 | 60 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 2 | 2008 | 324 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2014 | 230 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 139 | 0.110 |
Why?
|
| Neuroepithelial Cells | 1 | 2013 | 8 | 0.110 |
Why?
|
| Isoantigens | 1 | 1993 | 18 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1664 | 0.110 |
Why?
|
| Gelatinases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Microfilament Proteins | 2 | 2008 | 273 | 0.110 |
Why?
|
| Immunologic Surveillance | 2 | 1990 | 15 | 0.110 |
Why?
|
| Gene Silencing | 3 | 2009 | 238 | 0.110 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 34 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 208 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 261 | 0.100 |
Why?
|
| Mice, Inbred ICR | 1 | 2013 | 153 | 0.100 |
Why?
|
| Murine hepatitis virus | 1 | 2012 | 1 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2011 | 87 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 620 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 1993 | 145 | 0.100 |
Why?
|
| Cell Survival | 3 | 2020 | 807 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 421 | 0.100 |
Why?
|
| Physician's Role | 1 | 2014 | 164 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 1990 | 204 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 470 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2013 | 4783 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 1697 | 0.100 |
Why?
|
| Transfection | 2 | 2013 | 1069 | 0.100 |
Why?
|
| Adenoviruses, Human | 2 | 2003 | 81 | 0.100 |
Why?
|
| Thymidine Kinase | 5 | 2003 | 95 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2017 | 229 | 0.090 |
Why?
|
| Milk Proteins | 1 | 2011 | 92 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1992 | 275 | 0.090 |
Why?
|
| Time Factors | 5 | 2016 | 6309 | 0.090 |
Why?
|
| Urinary Bladder | 3 | 2019 | 245 | 0.090 |
Why?
|
| Biopsy | 3 | 2017 | 1239 | 0.090 |
Why?
|
| Transforming Growth Factors | 1 | 1990 | 20 | 0.090 |
Why?
|
| Sarcoma, Experimental | 1 | 1990 | 16 | 0.090 |
Why?
|
| Arthroplasty, Replacement | 1 | 2010 | 25 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 1990 | 27 | 0.080 |
Why?
|
| Neutrophils | 1 | 2012 | 379 | 0.080 |
Why?
|
| Cytosol | 6 | 1986 | 161 | 0.080 |
Why?
|
| Female | 19 | 2019 | 66553 | 0.080 |
Why?
|
| Ganciclovir | 4 | 2003 | 103 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 660 | 0.080 |
Why?
|
| Orthopedics | 1 | 1990 | 66 | 0.080 |
Why?
|
| Prognosis | 3 | 2022 | 4608 | 0.080 |
Why?
|
| Students, Medical | 1 | 2014 | 356 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2010 | 193 | 0.080 |
Why?
|
| Molecular Weight | 8 | 1995 | 392 | 0.080 |
Why?
|
| Chorioallantoic Membrane | 2 | 2019 | 12 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2003 | 199 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2018 | 329 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 672 | 0.080 |
Why?
|
| Cells, Cultured | 5 | 2007 | 3061 | 0.080 |
Why?
|
| Serpins | 1 | 2008 | 27 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2000 | 464 | 0.080 |
Why?
|
| Chick Embryo | 2 | 2019 | 132 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2000 | 658 | 0.070 |
Why?
|
| Cloning, Molecular | 2 | 2000 | 892 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 285 | 0.070 |
Why?
|
| Molybdenum | 2 | 1984 | 16 | 0.070 |
Why?
|
| Adenoviridae | 3 | 2000 | 605 | 0.070 |
Why?
|
| NF-kappa B | 2 | 2013 | 457 | 0.070 |
Why?
|
| Estrenes | 5 | 1986 | 21 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1113 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 137 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 1708 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2013 | 263 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2014 | 997 | 0.070 |
Why?
|
| Gene Transfer Techniques | 2 | 2017 | 357 | 0.070 |
Why?
|
| Culture Media | 3 | 1995 | 182 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 215 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 1008 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1228 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1587 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 532 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2010 | 539 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2006 | 47 | 0.070 |
Why?
|
| Receptors, Fc | 2 | 1998 | 29 | 0.060 |
Why?
|
| Neurons | 1 | 2016 | 1965 | 0.060 |
Why?
|
| Growth Substances | 2 | 2001 | 113 | 0.060 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2005 | 19 | 0.060 |
Why?
|
| DNA | 4 | 2000 | 1600 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 284 | 0.060 |
Why?
|
| Gene Expression | 2 | 2013 | 1570 | 0.060 |
Why?
|
| Testosterone Congeners | 2 | 1984 | 15 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 1998 | 40 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 2704 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 224 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 475 | 0.060 |
Why?
|
| Tritium | 3 | 1995 | 173 | 0.060 |
Why?
|
| Genistein | 1 | 2004 | 39 | 0.060 |
Why?
|
| Seminal Vesicles | 3 | 2013 | 55 | 0.060 |
Why?
|
| Sulfones | 1 | 2004 | 70 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2004 | 388 | 0.060 |
Why?
|
| Middle Aged | 6 | 2017 | 26717 | 0.060 |
Why?
|
| Cell Death | 1 | 2004 | 239 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 3881 | 0.060 |
Why?
|
| Recurrence | 2 | 2007 | 1425 | 0.060 |
Why?
|
| HIV-1 | 1 | 2007 | 467 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1998 | 1229 | 0.060 |
Why?
|
| Desmin | 1 | 2003 | 21 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1995 | 315 | 0.050 |
Why?
|
| Thymidine | 2 | 1995 | 54 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 152 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 157 | 0.050 |
Why?
|
| Aged | 5 | 2016 | 19692 | 0.050 |
Why?
|
| Exons | 2 | 2000 | 796 | 0.050 |
Why?
|
| Rats, Inbred Strains | 6 | 1992 | 234 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 348 | 0.050 |
Why?
|
| Lung | 3 | 2019 | 1491 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 276 | 0.050 |
Why?
|
| RNA | 1 | 1986 | 568 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 414 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 2142 | 0.050 |
Why?
|
| Uridine Diphosphate | 1 | 2022 | 5 | 0.050 |
Why?
|
| Neoplastic Processes | 1 | 2022 | 6 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 153 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2003 | 581 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 237 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 543 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2000 | 314 | 0.050 |
Why?
|
| Organ Culture Techniques | 2 | 1992 | 154 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 265 | 0.050 |
Why?
|
| Adult | 4 | 2014 | 29472 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 69 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2001 | 91 | 0.050 |
Why?
|
| Swine | 2 | 2004 | 1173 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1351 | 0.050 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2001 | 123 | 0.050 |
Why?
|
| Haplorhini | 1 | 2020 | 123 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2001 | 266 | 0.040 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2000 | 32 | 0.040 |
Why?
|
| Young Adult | 1 | 2014 | 8987 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2000 | 139 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 349 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 67 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 580 | 0.040 |
Why?
|
| Fetus | 2 | 1995 | 584 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 427 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1990 | 81 | 0.040 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 6 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 2538 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 571 | 0.040 |
Why?
|
| Introns | 1 | 2000 | 301 | 0.040 |
Why?
|
| Genes | 1 | 2000 | 445 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2000 | 226 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2000 | 270 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 92 | 0.040 |
Why?
|
| U937 Cells | 1 | 2018 | 25 | 0.040 |
Why?
|
| Connexin 43 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 626 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 39 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 764 | 0.040 |
Why?
|
| Everolimus | 1 | 2018 | 46 | 0.040 |
Why?
|
| Rabbits | 2 | 1998 | 711 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 753 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 1761 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 354 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 222 | 0.040 |
Why?
|
| Americas | 1 | 2018 | 50 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2020 | 372 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1998 | 49 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 44 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 49 | 0.040 |
Why?
|
| Lymphokines | 1 | 1998 | 66 | 0.040 |
Why?
|
| Breast | 1 | 2019 | 216 | 0.040 |
Why?
|
| Virus Cultivation | 1 | 2018 | 76 | 0.040 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 19 | 0.040 |
Why?
|
| Chemical Phenomena | 4 | 1992 | 85 | 0.040 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2017 | 4 | 0.040 |
Why?
|
| Chromatography, Gel | 2 | 1995 | 97 | 0.040 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2017 | 10 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 1082 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1998 | 100 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 221 | 0.030 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2018 | 242 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 177 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 1341 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 124 | 0.030 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 115 | 0.030 |
Why?
|
| Simplexvirus | 3 | 2003 | 104 | 0.030 |
Why?
|
| Chemistry, Physical | 3 | 1992 | 31 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 768 | 0.030 |
Why?
|
| Kinetics | 3 | 1995 | 1325 | 0.030 |
Why?
|
| Affinity Labels | 3 | 1984 | 15 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1995 | 69 | 0.030 |
Why?
|
| Vitamin D | 1 | 2017 | 159 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 504 | 0.030 |
Why?
|
| Histology | 1 | 1995 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2015 | 20 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 1998 | 410 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 803 | 0.030 |
Why?
|
| MEDLINE | 1 | 1995 | 20 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1995 | 65 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2005 | 459 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 249 | 0.030 |
Why?
|
| Species Specificity | 2 | 2013 | 550 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2006 | 139 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 528 | 0.030 |
Why?
|
| Estradiol | 2 | 1992 | 535 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 342 | 0.030 |
Why?
|
| Testosterone | 7 | 1986 | 538 | 0.030 |
Why?
|
| Metribolone | 5 | 1986 | 29 | 0.030 |
Why?
|
| Behavior | 1 | 2014 | 74 | 0.030 |
Why?
|
| Binding, Competitive | 5 | 1984 | 186 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1028 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 573 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 54 | 0.030 |
Why?
|
| Calcium | 1 | 2018 | 1098 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1749 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 79 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 1993 | 101 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 186 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2013 | 113 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2017 | 778 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 151 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 1992 | 27 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1180 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1992 | 90 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 240 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 16296 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 724 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 300 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 937 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 39 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 1990 | 56 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1704 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2012 | 380 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1422 | 0.020 |
Why?
|
| Graft Rejection | 2 | 1992 | 590 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 188 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1987 | 105 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1992 | 325 | 0.020 |
Why?
|
| United Kingdom | 1 | 2010 | 191 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 121 | 0.020 |
Why?
|
| DNA Replication | 1 | 1992 | 351 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1986 | 97 | 0.020 |
Why?
|
| Clone Cells | 1 | 1990 | 168 | 0.020 |
Why?
|
| Progesterone | 1 | 1992 | 625 | 0.020 |
Why?
|
| Chromatography, Affinity | 2 | 1986 | 70 | 0.020 |
Why?
|
| Keratins | 1 | 2009 | 55 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 6521 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1990 | 203 | 0.020 |
Why?
|
| Plasmids | 1 | 1990 | 514 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2817 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 94 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 1988 | 38 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 665 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3590 | 0.020 |
Why?
|
| Organogenesis | 1 | 2008 | 79 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 204 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
| Coronavirus Infections | 1 | 2012 | 359 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 35 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 229 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 701 | 0.020 |
Why?
|
| Cellulose | 1 | 1986 | 19 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2003 | 747 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 196 | 0.020 |
Why?
|
| Subcellular Fractions | 2 | 2003 | 98 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 25 | 0.020 |
Why?
|
| Gap Junctions | 1 | 2006 | 38 | 0.020 |
Why?
|
| Nandrolone | 1 | 1986 | 4 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 456 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2006 | 55 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 162 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 1616 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 615 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 141 | 0.020 |
Why?
|
| Sertoli Cells | 1 | 1985 | 78 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2008 | 1010 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 258 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1984 | 177 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 303 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2003 | 25 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2003 | 93 | 0.010 |
Why?
|
| Mitomycin | 1 | 2003 | 49 | 0.010 |
Why?
|
| Uterus | 1 | 1987 | 570 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 230 | 0.010 |
Why?
|
| Infant | 1 | 1998 | 12482 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1988 | 1017 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 410 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 237 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2003 | 297 | 0.010 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 1981 | 67 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2003 | 191 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 812 | 0.010 |
Why?
|
| Binding Sites | 1 | 1984 | 1297 | 0.010 |
Why?
|
| Methotrexate | 1 | 2003 | 341 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3726 | 0.010 |
Why?
|
| Herpesviridae | 1 | 2000 | 32 | 0.010 |
Why?
|
| Adolescent | 1 | 1998 | 19328 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2880 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 2000 | 55 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1247 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1691 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2000 | 437 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 10272 | 0.010 |
Why?
|
| Child | 1 | 1998 | 24453 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1997 | 762 | 0.010 |
Why?
|
| Cattle | 2 | 1987 | 566 | 0.010 |
Why?
|
| Castration | 2 | 1984 | 33 | 0.010 |
Why?
|
| Chimera | 1 | 1992 | 88 | 0.010 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1992 | 106 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 5811 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1990 | 41 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 1990 | 53 | 0.010 |
Why?
|
| Curriculum | 1 | 1995 | 723 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 65 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1988 | 193 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1987 | 50 | 0.000 |
Why?
|
| Epididymis | 1 | 1987 | 54 | 0.000 |
Why?
|
| Epitopes | 1 | 1988 | 431 | 0.000 |
Why?
|
| Chemistry | 1 | 1986 | 60 | 0.000 |
Why?
|
| Promegestone | 1 | 1986 | 31 | 0.000 |
Why?
|
| Androgen-Binding Protein | 1 | 1985 | 26 | 0.000 |
Why?
|
| Receptors, FSH | 1 | 1985 | 16 | 0.000 |
Why?
|
| Heterochromatin | 1 | 1985 | 49 | 0.000 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1985 | 47 | 0.000 |
Why?
|
| Transferrin | 1 | 1985 | 51 | 0.000 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1984 | 43 | 0.000 |
Why?
|
| RNA, Ribosomal | 1 | 1985 | 63 | 0.000 |
Why?
|
| Inhibins | 1 | 1985 | 86 | 0.000 |
Why?
|
| Spectrophotometry | 1 | 1984 | 59 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1984 | 51 | 0.000 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1985 | 186 | 0.000 |
Why?
|
| Isoelectric Point | 1 | 1983 | 18 | 0.000 |
Why?
|
| Triamcinolone Acetonide | 1 | 1984 | 37 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1984 | 94 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1984 | 290 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1984 | 331 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 471 | 0.000 |
Why?
|
| Receptors, Progesterone | 1 | 1986 | 879 | 0.000 |
Why?
|
| Chickens | 1 | 1981 | 638 | 0.000 |
Why?
|
| Estradiol Congeners | 1 | 1979 | 3 | 0.000 |
Why?
|
| Vacuoles | 1 | 1979 | 24 | 0.000 |
Why?
|
| Mitochondria, Muscle | 1 | 1979 | 35 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1979 | 153 | 0.000 |
Why?
|
| Atrophy | 1 | 1979 | 235 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1979 | 254 | 0.000 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1979 | 195 | 0.000 |
Why?
|